News & Updates
Filter by Specialty:
Icodec with app superior to OD analogues in insulin-naive T2D
Once-weekly insulin icodec with a dosing guide app is better than once-daily (OD) basal insulin analogues at reducing glycated haemoglobin (HbA1c) and improving treatment satisfaction and compliance in patients with type 2 diabetes (T2D), a study has shown. In addition, hypoglycaemia rates were low and similar between treatment groups.
Icodec with app superior to OD analogues in insulin-naive T2D
05 Oct 2023
Adjuvant trastuzumab for HER2-positive early BC: 9 weeks or 1 year?
For patients with HER2-positive early breast cancer (BC), 1 year of adjuvant trastuzumab remains standard of care (SoC) as noninferiority is not demonstrated for a shortened 9-week course of treatment in the final analysis of the phase III ShortHER trial. However, long-term data from the trial provide reassurance in case early discontinuation is needed in low-risk patients.
Adjuvant trastuzumab for HER2-positive early BC: 9 weeks or 1 year?
05 Oct 2023
Increasing BP level in late adolescence ups risk of cardiovascular events
Rising levels of blood pressure (BP), starting at 120/80 mm Hg, during late adolescence contribute to a gradual elevation in the risk of major cardiovascular events, reports a study in Sweden.
Increasing BP level in late adolescence ups risk of cardiovascular events
04 Oct 2023
Combination therapy with olmesartan safe, effective in advanced hypertension
Use of olmesartan in a combination therapy for advanced hypertension results in similar cardiovascular outcomes, including myocardial infarction (MI), relative to active comparators, according to a study. Additionally, there is no convincing evidence that olmesartan is harmful to patients with hypertension.
